Advances in cervical cancer treatment

Gynecologic Oncology

Volumn 121, Issue 3, 2011, Pages 431-433

  Downs, Levi ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM; STEM CELL FACTOR RECEPTOR; TOPOTECAN; VASCULOTROPIN RECEPTOR; VIRUS DNA; WART VIRUS VACCINE;

ABDOMINAL TRACHELECTOMY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLPOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONDYLOMA ACUMINATUM; CONSERVATIVE TREATMENT; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; FEMALE FERTILITY; FOLLOW UP; GENITAL SYSTEM DISEASE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTHERMIA; LAPAROSCOPIC SURGERY; LOOP ELECTRICAL EXCISION PROCEDURE; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPANICOLAOU TEST; PATIENT SAFETY; PELVIS LYMPHADENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLICY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PREGNANCY COMPLICATION; PREGNANCY RATE; PREMATURE LABOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT CANCER; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; VAGINAL RADICAL TRACHELECTOMY;

FEMALE; HUMANS; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 79957446230     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.010     Document Type: Editorial

References (26)

1. Jemal A, Siegel R, Xu J, and Ward E Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
3. Pecorelli S, Zigliani L, and Odicino F Revised FIGO staging for carcinoma of the cervix Int J Gynaecol Obstet 105 2009 107 108
4. Horn LC, Fischer U, Raptis G, Bilek K, and Hentschel B Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer Gynecol Oncol 107 2007 310 315 (Pubitemid 47575730)
5. Garland SM, Hernandez-Avila M, and Wheeler CM Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 2007 1928 1943 (Pubitemid 46740303)
6. Paavonen J, Naud P, and Salmerón J Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
7. ACOG Committee on Practice Bulletins-Gynecology ACOG Practice Bulletin no. 109: Cervical cytology screening Obstet Gynecol 114 2009 1409 1420
8. Wright TC Jr, Massad LS, and Dunton CJ 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Am J Obstet Gynecol 197 2007 346 355 (Pubitemid 47464164)
9. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Am J Obstet Gynecol 197 2007 346 355 (Pubitemid 47464164)
10. Moscicki AB, Shiboski S, and Hills NK Regression of low-grade squamous intra-epithelial lesions in young women Lancet 364 2004 1678 1683 (Pubitemid 39458143)
11. Jakobsson M, Gissler M, Paavonen J, and Tapper AM Loop electrosurgical excision procedure and the risk for preterm birth Obstet Gynecol 114 2009 504 510
12. Cervista HPV 16/18 package insert. http://www.cervistahpv.com/pdf/ Cervista-HPV-16-18-PI-15-3101-Rev-B.pdf
13. ASCCP consensus guidelines: Use of HPV genotyping to manage HPV HR positive/cytology negative women 30 years and older. http://www.asccp.org/ Portals/9/docs/pdfs/Consensus %20Guidelines/hpv-genotyping-20090320.pdf
14. Kim YT, Lee JM, Hur SY, Cho CH, Kim YT, Kim SC, and Kang SB Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia Int J Cancer 126 2010 1903 1909
15. Cuzick J, Arbyn M, and Sankaranarayanan R Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 Suppl 10 2008 K29 41
16. Ronco G, Giorgi-Rossi P, and Carozzi F Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test J Natl Cancer Inst 100 2008 492 501
17. Naucler P, Ryd W, and Törnberg S Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening J Natl Cancer Inst 101 2009 88 99
18. Rob L, Skapa P, and Robova H Fertility-sparing surgery in patients with cervical cancer Lancet Oncol 12 2011 192 200
19. Beiner ME, Hauspy J, and Rosen B Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: a matched case-control study Gynecol Oncol 110 2008 168 171
20. Schmeler KM, Frumovitz M, and Ramirez PT Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol 120 2011 Mar 321 325
21. A. Duenas-Gonzalez, J.J. Zarba, and J.C. Alcedo A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix J Clin Oncol 27 18 Supplement 2009 CRA5507
22. Kitchener HC, Hoskins W, Small W Jr, Thomas GM, and Trimble EL The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report Int J Gynecol Cancer 20 2010 1092 1100
23. Monk BJ, Sill MW, and McMeekin DS Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
24. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, and Roman LD Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 27 2009 1069 1074
25. Monk BJ, Willmott LJ, and Sumner DA Anti-angiogenesis agents in metastatic or recurrent cervical cancer Gynecol Oncol 116 2010 Feb 181 186
26. Monk BJ, Mas Lopez L, and Zarba JJ Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 2010 3562 3569